Inspira Technologies has received US patent approval for its orbiting blood oxygenation delivery system (VORTX).

This system is a key component of the INSPIRA ART500 device, which is designed to enable breathing in patients who are awake, by measuring the real-time blood parameters of the patient continuously and delivering the necessary oxygen volume straight into the blood.

Inspira said the patented technology has 16 claims that have been recognised as novel.

The VORTX system is engineered to oxygenate blood while eliminating the use of fibre membranes.

Traditional fibre oxygenators force blood through layers of fibres, creating a turbulent flow that can lead to high hemolysis, damage to white blood cells, and activation of the body's inflammatory and immune responses.

The VORTX system is capable of maintaining a more natural flow of blood, potentially reducing these harmful effects.

Inspira expects the orbiting blood oxygenation delivery system to be a transformative technology for the INSPIRA ART500 device, which is targeting the $19bn mechanical ventilation market.

Inspira Technologies CEO Dagi Ben-Noon: “We believe that this is a monumental advancement in the landscape of blood oxygenation technologies and a pivotal milestone and another key indicator of the INSPIRA ART500's core technological portfolio.”

To be equipped with Inspira’s HYLA blood sensor, the INSPIRA ART500 is being designed to scan the patient's blood continuously.

In December 2023, Inspira reported that its HYLA blood sensor line (blood sensor) achieved 95% accuracy versus conventional blood gas analysers.

Said to be highly precise, not invasive, durable and a versatile tool for various procedures, the new sensor technology could provide continuous and real-time data collection and analysis of blood samples.